A major Novartis shareholder urges board changes to improve oversight after drug trial failures and significant share price declines. Read more at straitstimes.com. Read more at straitstimes.com.

Shares of Novartis tanked on Tuesday after results from its del-desiran drug trial disappointed investors.

Shares in the market heavyweight plummeted by over 10% at one point during early trading on Tuesday following the failure of a trial into a drug for a muscle disorder.